CBLL Ceribell, Inc.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1861107 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY31.3%
TTM net income YoY-40.8%
TTM EPS YoY-467.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin89.3%
Operating margin-69.8%
Net margin-68.0%
FCF margin-51.9%
EBITDA margin-68.9%
Returns
ROE-52.5%
ROA-41.5%
ROIC (approx.)-55.5%
Asset turnover0.61x
Leverage & solvency
Liabilities / assets24.8%
Debt / equity0.00x
Current ratio8.18x
Interest coverage-47.39x
Cash quality & payout
Operating cash flow / net income0.76x
Accruals ratio-10.0%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $29.34M | $28.10M | $26.49M | $24.78M | $22.59M | $21.20M | $20.49M | $18.53M |
| Cost of revenue | $3.00M | $2.16M | $3.37M | $3.14M | $2.65M | $2.52M | $2.48M | $2.30M |
| Gross profit | $26.34M | $25.94M | $23.12M | $21.64M | $19.94M | $18.68M | $18.01M | $16.24M |
| R&D expense | $7.40M | $6.75M | $6.16M | $5.06M | $4.98M | $4.85M | $4.25M | $3.91M |
| SG&A expense | $14.45M | $14.76M | $15.32M | $12.12M | $11.04M | $11.36M | $9.94M | $9.97M |
| Operating income | -$20.55M | -$19.98M | -$20.75M | -$14.60M | -$14.65M | -$14.95M | -$14.21M | -$12.88M |
| Interest expense | $267,000 | $438,000 | $434,000 | $462,000 | $480,000 | $477,000 | $471,000 | $499,000 |
| Pretax income | -$21.35M | -$19.27M | -$19.74M | -$13.53M | -$13.46M | -$13.64M | -$12.78M | -$12.58M |
| Income tax | $0 | $0 | — | $0 | $0 | $0 | — | — |
| Net income | -$21.35M | -$19.27M | -$19.74M | -$13.53M | -$13.46M | -$13.64M | -$12.78M | -$12.58M |
| EBITDA | -$20.35M | -$19.78M | -$20.51M | -$14.30M | -$14.35M | -$14.75M | -$13.87M | -$12.52M |
| EPS (basic) | -0.55 | -0.51 | -0.52 | — | -0.37 | -0.38 | -0.36 | — |
| EPS (diluted) | -0.55 | -0.51 | -0.52 | — | -0.37 | -0.38 | -0.36 | — |
| Weighted avg. shares (diluted) | 38.50M | 38.03M | 37.66M | — | 36.81M | 36.29M | 35.88M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $41.99M | $32.66M | $45.25M | $40.48M | $23.74M | $40.14M | $153.36M | $194.37M |
| Short-term investments | $75.48M | $96.60M | $95.93M | $118.78M | $144.80M | $137.29M | $29.34M | — |
| Receivables | $17.79M | $15.99M | $15.71M | $15.05M | $12.23M | $12.31M | $11.30M | $10.88M |
| Inventory | $6.96M | $6.74M | $6.90M | $7.29M | $6.02M | $6.00M | $6.55M | $6.94M |
| Current assets | $147.44M | $157.85M | $168.91M | $186.72M | $191.81M | $199.79M | $205.42M | $217.27M |
| PP&E, net | $1.77M | $1.76M | $1.93M | $2.03M | $2.06M | $2.10M | $2.12M | $2.31M |
| Total assets | $156.37M | $166.35M | $178.08M | $195.80M | $199.53M | $207.69M | $213.47M | $225.41M |
| Current liabilities | $18.03M | $17.20M | $16.18M | $19.19M | $15.17M | $15.01M | $11.83M | $12.99M |
| Total liabilities | $38.83M | $38.03M | $37.27M | $40.47M | $35.44M | $35.53M | $32.59M | $34.25M |
| Shareholders' equity | $117.54M | $128.31M | $140.81M | $155.34M | $164.08M | $172.16M | $180.88M | $191.16M |
| Shares outstanding | 38.82M | 38.22M | 37.86M | 37.49M | 37.05M | 36.60M | 35.90M | 35.85M |
| Cash flow statement | ||||||||
| Operating cash flow | -$13.08M | -$12.86M | -$19.30M | -$10.77M | -$11.10M | -$7.53M | -$11.40M | -$9.97M |
| Capital expenditure | $100,000 | $17,000 | $125,000 | $179,000 | $369,000 | $71,000 | $148,000 | $357,000 |
| Free cash flow | -$13.18M | -$12.88M | -$19.42M | -$10.95M | -$11.47M | -$7.60M | -$11.55M | -$10.33M |
| Investing cash flow | $20.82M | -$606,000 | $22.44M | $26.11M | -$6.94M | -$107.69M | -$29.61M | -$493,000 |
| Financing cash flow | $1.58M | $880,000 | $1.63M | $1.40M | $1.64M | $2.01M | $2,000 | $190.73M |
| Depreciation & amortization | $200,000 | $200,000 | $239,000 | $291,000 | $300,000 | $200,000 | $335,000 | $364,000 |
| Stock-based compensation | $7.10M | $6.00M | $3.72M | $3.36M | $3.35M | $3.17M | $2.35M | $2.20M |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.